AU2005261687B8 - Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor - Google Patents

Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor Download PDF

Info

Publication number
AU2005261687B8
AU2005261687B8 AU2005261687A AU2005261687A AU2005261687B8 AU 2005261687 B8 AU2005261687 B8 AU 2005261687B8 AU 2005261687 A AU2005261687 A AU 2005261687A AU 2005261687 A AU2005261687 A AU 2005261687A AU 2005261687 B8 AU2005261687 B8 AU 2005261687B8
Authority
AU
Australia
Prior art keywords
app
binding
kit according
amino acid
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005261687A
Other languages
English (en)
Other versions
AU2005261687A1 (en
AU2005261687B2 (en
Inventor
Frank Mattner
Walter Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris Forschungs und Entwicklungs GmbH
Original Assignee
Affiris Forschungs und Entwicklungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Forschungs und Entwicklungs GmbH filed Critical Affiris Forschungs und Entwicklungs GmbH
Publication of AU2005261687A1 publication Critical patent/AU2005261687A1/en
Application granted granted Critical
Publication of AU2005261687B2 publication Critical patent/AU2005261687B2/en
Publication of AU2005261687B8 publication Critical patent/AU2005261687B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
AU2005261687A 2004-07-13 2005-07-06 Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor Ceased AU2005261687B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
ATA1185/2004 2004-07-13
PCT/EP2005/053224 WO2006005706A2 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimer´schen erkrankung sowie kit hierfür

Publications (3)

Publication Number Publication Date
AU2005261687A1 AU2005261687A1 (en) 2006-01-19
AU2005261687B2 AU2005261687B2 (en) 2011-02-17
AU2005261687B8 true AU2005261687B8 (en) 2011-07-21

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005261687A Ceased AU2005261687B8 (en) 2004-07-13 2005-07-06 Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor

Country Status (14)

Country Link
US (2) US7935348B2 (cg-RX-API-DMAC7.html)
EP (1) EP1765388B8 (cg-RX-API-DMAC7.html)
JP (2) JP5642333B2 (cg-RX-API-DMAC7.html)
KR (1) KR101158600B1 (cg-RX-API-DMAC7.html)
CN (1) CN101022825B (cg-RX-API-DMAC7.html)
AT (1) AT500483B1 (cg-RX-API-DMAC7.html)
AU (1) AU2005261687B8 (cg-RX-API-DMAC7.html)
CA (1) CA2577332C (cg-RX-API-DMAC7.html)
DK (1) DK1765388T3 (cg-RX-API-DMAC7.html)
ES (1) ES2414872T3 (cg-RX-API-DMAC7.html)
PL (1) PL1765388T3 (cg-RX-API-DMAC7.html)
PT (1) PT1765388E (cg-RX-API-DMAC7.html)
TW (1) TW200602072A (cg-RX-API-DMAC7.html)
WO (1) WO2006005706A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
HRP20140240T4 (hr) * 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AR064501A1 (es) * 2006-12-22 2009-04-08 Genentech Inc Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8586706B2 (en) * 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
AU2009313851A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
CA2748561C (en) 2008-12-22 2016-11-01 Kaneka Corporation A.beta. remover, a.beta. removing apparatus and a.beta. removal system
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
CA2853961C (en) 2011-11-01 2016-09-20 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
WO2013140785A1 (ja) * 2012-03-18 2013-09-26 国立大学法人九州大学 疾患サンプル分析装置、分析システム及び分析方法
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DK2834643T3 (da) 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer
EP2834644B1 (de) 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
WO2017197253A2 (en) * 2016-05-12 2017-11-16 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
US20200164008A1 (en) * 2017-07-17 2020-05-28 Spark Therapeutics, Inc. Apheresis methods and uses
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
AU691297B2 (en) 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
ES2175325T3 (es) 1997-06-18 2002-11-16 Morse Tec Europe Srl Rueda dentada con perfil de dientes mejorado para funcionamiento mas silencioso.
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002533169A (ja) 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Also Published As

Publication number Publication date
AT500483B1 (de) 2006-01-15
KR101158600B1 (ko) 2012-07-09
WO2006005706A3 (de) 2006-07-20
EP1765388B1 (de) 2013-04-17
JP2008506665A (ja) 2008-03-06
DK1765388T3 (da) 2013-07-22
ES2414872T8 (es) 2014-11-06
CN101022825B (zh) 2015-02-04
CA2577332A1 (en) 2006-01-19
AU2005261687A1 (en) 2006-01-19
EP1765388A2 (de) 2007-03-28
CN101022825A (zh) 2007-08-22
JP5642333B2 (ja) 2014-12-17
US20110201987A1 (en) 2011-08-18
WO2006005706A2 (de) 2006-01-19
TW200602072A (en) 2006-01-16
AU2005261687B2 (en) 2011-02-17
EP1765388B8 (de) 2013-05-29
TWI350173B (cg-RX-API-DMAC7.html) 2011-10-11
CA2577332C (en) 2014-12-09
US20080051690A1 (en) 2008-02-28
ES2414872T3 (es) 2013-07-23
PT1765388E (pt) 2013-05-24
US7935348B2 (en) 2011-05-03
PL1765388T3 (pl) 2013-09-30
WO2006005706A8 (de) 2006-11-16
AT500483A4 (de) 2006-01-15
JP2013116903A (ja) 2013-06-13
KR20070036158A (ko) 2007-04-02
HK1103354A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
AU2005261687B8 (en) Combination therapy for the prevention or treatment of Alzheimer's disease as well as kit therefor
US20060030027A1 (en) Capture and removal of biomolecules from body fluids using partial molecular imprints
Marciani Promising results from Alzheimer’s disease passive immunotherapy support the development of a preventive vaccine
IL298215A (en) A multi-epitope vaccine for the treatment of Alzheimer's disease
AU2004271651B2 (en) Apheresis device
KR20230087495A (ko) 알츠하이머 질환을 치료하기 위한 β-아밀로이드 백신
KR20230087499A (ko) 알츠하이머 질환 치료용 멀티에피토프 백신
IL300346A (en) TAU vaccine for the treatment of Alzheimer's disease
Boada et al. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study
Li et al. Enhancing antigen presentation and inducing antigen-specific immune tolerance with amphiphilic peptides
JPH0912462A (ja) Ｔ４リンパ球へのｌａｖウイルス感染を防止する方法
US8906382B2 (en) Method for treating amyloid disease
RU2582389C2 (ru) ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ БЕЛКА β2m
Triplett et al. Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
HK1103354B (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
UA60331C2 (uk) Спосіб лікування розсіяного склерозу
US20250134973A1 (en) Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
Decourtb et al. Active Immunization Targeting Amyloid β for the Treatment of AlzheimerLs
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease
HK1255676A1 (en) THERAPEUTIC USE OF THE ß2M PROTEIN
KR20070021102A (ko) 아페레시스 장치

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMBINATION THERAPY FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE AS WELL AS KIT THEREFOR

TH Corrigenda

Free format text: IN VOL 25, NO 7, PAGE(S) 815 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME AFFIRIS FORSCHUNGS-UND ENTWICKLUNGS GMBH, APPLICATION NO.2005261687, UNDER INID (54) CORRECT THE TITLE TO READ COMBINATION THERAPY FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE AS WELL AS KIT THEREFOR

MK14 Patent ceased section 143(a) (annual fees not paid) or expired